Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

All Drugs and Chemicals

Antineoplastic Agents

Anti-Infective Agents

Hormones

Everolimus

Sirolimus

Temsirolimus

MTOR Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Immunosuppressive Agents

Immunologic Factors

Self-administered as a daily dose of 10mg orally

everolimus

The purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide guidance to the Physician for the treatment and monitoring of patients in the Cohort MAP.

Prior to inclusion of a patient in the Cohort, the requesting Physician must submit a request for access to the product in GEMS (Grants, External Requests and Managed Access System) accessible through https://www.novartis.com/our-focus/healthcare-professionals/managedaccess-programs providing the rationale for the request and relevant medical history of the patient.

The request is then assessed against the MAP and Cohort inclusion/exclusion criteria by the medical team experienced with the product and indication. Upon the required approvals, the patient is included in the Cohort.

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Managed Access Program (MAP) Cohort Treatment Plan CRAD001Y2002M to Provide Access to Afinitor for Patients With Advanced Hormone Receptor Positive (HR+) Breast Cancer

Novartis Pharmaceuticals

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer	NCT05108740	Advanced Hormon...	everolimus	18 Years - 99 Years	Novartis
MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer	NCT05108740	Advanced Hormon...	everolimus	18 Years - 99 Years	Novartis

Spots Global Cancer Trial Database for advanced hormone receptor positive (hr+) breast cancer